Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 2b open-label & single-arm study to evaluate pharmacokinetics& efficacy& safety and tolerability of letermovir in pediatric participants from birth to <18 years of age at risk of developing CMV infection and/or disease following allogeneic HSCT
Protocol ID
MK-8228-030
Disease (Sub Disease)
Cytomegalovirus (CMV) Infection
Diagnosis Stage
New Diagnosis
Relapse/Refractory
Location
NSW, QLD, VIC
Sponsor
Merck Sharp & Dohme Corp.
Trial Status
Open
Sites
The Children's Hospital at Westmead
Queensland Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
up to 17 years
International registry ID's
NCT03940586
Back to Registry
Study Title A Phase 2b open-label & single-arm study to evaluate pharmacokinetics& efficacy& safety and tolerability of letermovir in pediatric participants from birth to <18 years of age at risk of developing CMV infection and/or disease following allogeneic HSCT
Protocol ID MK-8228-030
Disease (Sub Disease) Cytomegalovirus (CMV) Infection
Diagnosis Stage New Diagnosis
Relapse/Refractory
Location NSW / QLD / VIC
Sponsor Merck Sharp & Dohme Corp.
Links https://clinicaltrials.gov/ct2/show/NCT03940586
Trial Status Open
Trial Open Date 08/08/2019
Sites The Children's Hospital at Westmead / Queensland Children's Hospital / Royal Children's Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility up to 17 years
International registry ID's NCT03940586